SCHEMBL4019668

SCHEMBL4019668

Cc1c(F)cccc1[C@H]1[C@@H](C(=O)c2cccc(O)c2)CN(CCO)C[C@@H]1C(=O)c1cccc(F)c1F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH2 P25021 1/20 0.34
HRH1 P35367 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
TAS1R2 Q8TE23 1/20 0.33
HCRTR1 O43613 2/20 0.32
HCRTR2 O43614 2/20 0.32
KDM2B Q8NHM5 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
NPC1 O15118 1/20 0.31
TNF P01375 1/20 0.31
RAB9A P51151 1/20 0.31
NOD1 Q9Y239 1/20 0.31
MGLL Q99685 1/20 0.31
PARP1 P09874 1/20 0.30
PARP2 Q9UGN5 1/20 0.30
EED O75530 1/20 0.30
MC4R P32245 1/20 0.30
ESRRG P62508 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4024566 0.95 EED (0.33) HRH2HRH1TAS1R3TAS1R1TAS1R2
SCHEMBL4029269 0.95 KDM2B (0.35) HRH2HRH1TAS1R3TAS1R1TAS1R2
SCHEMBL4028155 0.94 KMT2A (0.34) TAS1R3TAS1R1TAS1R2HCRTR1HCRTR2
SCHEMBL4020633 0.93 MEN1 (0.35) KDM2BMEN1KMT2AMGLLMC4R
SCHEMBL4022598 0.93 MEN1 (0.35) TAS1R3TAS1R1TAS1R2KDM2BMEN1
SCHEMBL4751303 0.90 KDM2B (0.33) KDM2BMEN1KMT2AMGLLMC4R
SCHEMBL4025770 0.86 KDM2B (0.41) KDM2BMEN1KMT2AMGLL
SCHEMBL4022073 0.86 MEN1 (0.36) KDM2BMEN1KMT2AMGLLMC4R
SCHEMBL4020144 0.86 DPP4 (0.38) KDM2BMGLLMC4R
SCHEMBL13720775 0.86 MEN1 (0.35) KDM2BMEN1KMT2AMGLLPARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US claimed
US-7572814-B2 3,5-dibenzoyl-4-phenyl-piperidine anti-cancer compounds CYTOKINETICS, INCORPORATED (US) 2009-08-11 US disclosed
EP-1962846-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-09-03 EP disclosed
US-20070161674-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2007-07-12 US disclosed
WO-2007059323-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161674-A1 Certain chemical entities, compositions, and methods TP53, VHL, RB1 HRH2 2374/4885HRH1 2806/4885TAS1R3 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.